Equity Research for the following companies: VeriFone (NYSE:PAY), Hewlett-Packard (NYSE:HPQ), eBay (NASDAQ:EBAY), Apple (NASDAQ:AAPL), J.C. Penney (NYSE:JCP), and Amylin Pharmaceuticals (NASDAQ:AMLN).

Equity Research for the following companies: Amylin Pharmaceuticals (NASDAQ:AMLN), Melco Crown Entertainment (NASDAQ:MPEL), Advanced Micro Devices (NYSE:AMD), Halliburton (NYSE:HAL), Petroleo Brasileiro SA (NYSE:PBR), and Netflix (NASDAQ:NFLX).

a dramatic change in circumstances requiring the Board to permit shareholders another opportunity to nominate directors and make proposals at the 2012 annual meeting of shareholders. Therefore, we demanded last week that the Board provide shareholders with a new 10-day period

still not acknowledged or denied the media reports regarding its rejection of a $22 per share takeover offer from Bristol-Myers Squibb. To this day, shareholders would not have known about this opportunity had the story not been leaked to the press. Still more egregious is the fact that, in the face of this reported $22 offer, the Board approved both (i) the public offering of 10% of the company at an assumed price of $15.62 per share on March 8th, without disclosing the Bristol-Myers offer in the registration statement that Amylin filed with the SEC (in this regard, we find it notable that not all members of the Board signed this registration statement), and (ii) the granting of options to the company's executive officers with an exercise price of $16.02 per share (approximately 27% below the reported $22 bid price from Bristol-Myers) on March 6th. These actions make absolutely no sense to me in light of a Bristol-Myers bid and have served to substantially dilute shareholders who owned the stock when these actions were taken. I believe any decision not to pursue a sale of the company at this time is a huge mistake

SAN DIEGO, April 3, 2012 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today announced that it has completed its Biologics License Application (BLA) submission to the U.S.